Fracture healing is delayed in the absence of gasdermin–interleukin-1 signaling

Kai Sun1,2,3, Chun Wang2, Jianqiu Xiao2, Michael D. Brodt4, Luorongxin Yuan2, Tong Yang1,2,3, Yael Alippe2, Huimin Hu3, Dingjun Hao1,3, Yousef Abu-Amer4,5, Matthew J. Silva4, Jie Shen4, Gabriel Mbalaviele2*

1 Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, China; 2 Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, MO 63110, USA; 3 Department of Spine Surgery, Honghui Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, China; 4 Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA; 5 Shriners Hospital for Children, St. Louis, Missouri, USA

Running title: Gasdermin – interleukin-1 signaling in fracture healing

*To whom correspondence should be addressed. Division of Bone and Mineral Diseases, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8301, St. Louis, MO 63110, Phone: (314) 286-1114; Fax: (314) 454-5047; e-mail: gmbalaviele@wustl.edu
Abstract

Amino-terminal fragments from proteolytically cleaved gasdermins (GSDMs) form plasma membrane pores that enable the secretion of interleukin-1β (IL-1β) and IL-18. Excessive GSDM-mediated pore formation can compromise the integrity of the plasma membrane thereby causing the lytic inflammatory cell death, pyroptosis. We found that GSDMD and GSDME were the only GSDMs that were readily expressed in bone microenvironment. Therefore, we tested the hypothesis that GSDMD and GSDME are implicated in fracture healing owing to their role in the obligatory inflammatory response following injury. We found that bone callus volume and biomechanical properties of injured bones were significantly reduced in mice lacking either GSDM compared with wild-type (WT) mice, indicating that fracture healing was compromised in mutant mice. However, compound loss of GSDMD and GSDME did not exacerbate the outcomes, suggesting shared actions of both GSDMs in fracture healing. Mechanistically, bone injury induced IL-1β and IL-18 secretion in vivo, a response that was mimicked in vitro by bone debris and ATP, which function as inflammatory danger signals. Importantly, the secretion of these cytokines was attenuated in conditions of GSDMD deficiency. Finally, deletion of IL-1 receptor reproduced the phenotype of Gsmd or Gsme deficient mice, implying that inflammatory responses induced by the GSDM-IL-1 axis promote bone healing after fracture.
Introduction

Bone fractures are one of the most frequent injuries of the musculoskeletal system. Despite advances in therapeutic interventions, delayed healing, compromised quality of the newly regenerated bone, or nonunions remain frequent outcomes of these injuries (1, 2). These outcomes are complicated by the advanced age of the patients, infection, or sterile inflammation-prone comorbidities such as rheumatoid arthritis or diabetes mellitus (1-3). Although the recovery speed from fracture is greater in small animals such as rodents than in large counterparts and humans, the underlying repair mechanisms are shared across species (3). Thus, mouse models, which are amenable to genetic manipulation, provide opportunities for shedding light onto the mechanisms of fracture healing.

Bone fracture triggers an immediate inflammatory response during which neutrophils and macrophages are mobilized to the injury site to remove necrotic cells and debris while releasing factors that initiate neovascularization and promote tissue repair by recruiting mesenchymal progenitor cells from various sites such as the periosteum and bone marrow (3-5). The repair phase is followed by remodeling events where the balanced activity of osteoblasts and osteoclasts culminates in the restoration of the original bone structure and bone marrow cavity (4, 6, 7). Ultimately, inflammation subsides stemming from the suppressive actions of immune cells such as regulatory T cells, anti-inflammatory macrophages, and mesenchymal stem cells (8-10). Although inflammation declines over time, interfering with its onset immediately after injury can be detrimental as mice lacking interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), or macrophages exhibit defective healing (11-17). Thus, a fine-tuned level of inflammation is critical for adequate fracture healing.

IL-1β is another inflammatory cytokine that impacts fracture healing (18, 19). Unlike the aforementioned cytokines, IL-1β and IL-18 lack the signal peptide for secretion through the conventional endoplasmic reticulum and Golgi route. Expressed as pro-IL-1β and pro-IL-18,
these polypeptides are proteolytically activated by enzymes such as caspase-1, a component of the intracellular macromolecular complexes called inflammasomes (20, 21). Caspase-1 also cleaves GSDMD, generating GSDMD amino-terminal fragments, which form plasma membrane pores through which IL-1β and IL-18 are secreted to the extracellular milieu (21, 22). Although live cells can secrete these cytokines, excessive GSDMD-dependent pore formation compromises the integrity of the plasma membrane, causing a lytic form of cell death known as pyroptosis (22, 23). Pyroptotic cells release not only IL-1β and IL-18 but also other inflammatory molecules including eicosanoids, nucleotides, and alarmins (21, 22, 24). Thus, the actions of GSDMD in inflammatory settings can extend beyond the sole secretion of IL-1β and IL-18, and need to be tightly regulated to maintain homeostasis.

GSDMD is a member of the GSDM family proteins, which are encoded by Gsdma1-3, Gsdmc1-4, Gsdmd, and Gsdme also known as Dnfa5 in the mouse genome (25). Mice lacking GSDMD are protected against multi-organ damage caused by gain-of-function mutations of nucleotide-binding oligomerization domain-like receptors family, pyrin domain containing 3 (NLRP3) or pyrin inflammasome (26, 27). GSDMD is also involved in the pathogenesis of complex diseases including experimental autoimmune encephalitis, radiation-induced tissue injury, ischemia/reperfusion injury, sepsis, renal fibrosis, and thrombosis (28-33). Other well studied GSDMs include GSDMA and GSDME (25, 34-36). GSDME is of particular interest to this study because recent evidence suggests that it harbors overlapping and non-overlapping actions with GSDMD, depending on cell contexts. Indeed, GSDME can mediate pyroptosis and release cytokines under both GSDMD sufficient and insufficient conditions (35, 37-40). Despite advances in GSDM studies, the role that these proteins play in fracture healing has not been studied. Since drugs for the treatment of GSDM-dependent inflammatory disorders and cancers are under development, it is imperative to understand their functions in the musculoskeletal system. Here, we found that loss of GSDMD or GSDME in mice impeded fracture healing.
through mechanisms involving IL-1 signaling. This discovery has translational implications as drugs that inhibit GSDM functions may contribute to unsatisfactory fracture healing outcomes.
Materials and methods

A revised ethics statement that includes any protocol or reference numbers associated with the ethical approval of your work.

Mice

Gsmd knockouts were kindly provided by Dr. V. M. Dixit (Genentech, South San Francisco, CA). All mice were on the C57BL6J background, and genotyping was performed by PCR. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Washington University School of Medicine in St. Louis. All experiments were performed in accordance with the relevant guidelines and regulations described in the IACUC-approved protocol 19-0971.

Tibia fracture model

Open mid-shaft tibia fractures were created unilaterally in 12-week-old mice. Briefly, a 6-mm long incision was made in the skin on the anterior side alongside the tibia. A sterile 26-G needle was inserted into the tibia marrow cavity from the proximal end, temporarily withdrawn to allow transection of the tibia with a scalpel at mid-shaft, and then reinserted and secured. The incision was closed with 5-0 nylon sutures. Mice were sacrificed at different time-points as indicated below.

Histological analyses of fracture calluses

Fractured tibias were collected on day 7, 10, 14, 21, and 28 after fracture for histological analyses. Excess muscle and soft tissue were excised. Tibias were fixed in 10% neutral-buffered formalin for 24 hours and decalcified for 10-14 days in 14% ethylenediaminetetraacetic acid solution (pH 7.2). Tissue was processed and embedded in paraffin, and sectioned longitudinally at a thickness of 5 μm. Alcian blue/hematoxylin/orange-g (ABH/OG) and tartrate-
resistant acid phosphatase (TRAP) staining were performed to analyze the callus composition and osteoclast formation in the fracture region. Images were acquired using ZEISS microscopy (Carl Zeiss Industrial Metrology, MN). Cartilage area, bone area, mesenchyme area, and osteoclast parameters were quantified on ABH/OG, TRAP-stained sections using NIH ImageJ software 1.52a (Wayne Rasband) and Bioquant (41).

Micro-computed tomography analysis

After careful dissection and removal of the intramedullary pins in fractured tibias, fracture calluses were examined using micro-computed tomography system (μCT 40 scanner, Scanco Medical AG, Zurich) scanner at 10 μm, 55 kVp, 145 μA, 300 ms integration time. Six hundred slices (6.3 mm) centered on the callus midpoint were used for micro-CT analyses. A contour was drawn around the margin of the entire callus and a lower threshold of 180 per mille was then applied to segment mineralized tissue (all bone inside the callus). A higher threshold of 340 per mille was applied to segment the original cortical bone inside the callus volume. Quantification for the volumes of the bone calluses was performed using the Scanco analysis software. 3D images were generated using a constant threshold of 180 per mille for the diaphyseal callus region of the fractured tibia.

Biomechanical torsion testing

Tibias were collected 28 days after fracture and moistened with PBS and stored at -20°C until they were thawed for biomechanical testing. Briefly, the ends of the samples were potted with methacrylate (MMA) bone cement (Lang Dental Manufacturing) in 1.2-cm-long cylinders (6-mm diameter). The fracture site was kept in the center of the two potted ends with roughly 4.2-mm of the bone exposed. After MMA solidification, potted bones were set up on a custom torsion machine. One end of the potted specimen was held in place while the opposing end was
rotated at 1 degree per second until fracture. Torque values were plotted against the rotational deformation, and the maximum torque, torsional rigidity, and work to fracture were calculated.

**Cell cultures**

Murine primary bone marrow-derived macrophages (BMDMs) were obtained by culturing mouse bone marrow cells from femurs and tibias in culture media containing a 1:10 dilution of supernatant from the fibroblastic cell line CMG 14-12 as a source of macrophage colony-stimulating factor, a mitogenic factor for BMDMs, for 4-5 days in a 15-cm dish as previously described (29, 42). After expansion, BMDMs were plated at a density of 1 x 10^6 cells/well in 6-well plate for experiments.

Murine primary neutrophils were isolated by collecting bone marrow cells and subsequently over a discontinuous Percoll (Sigma) gradient. Briefly, all bone marrow cells from femurs and tibias were washed by DPBS and then resuspend in 2 mL DPBS. Cell suspension was gently layered on top of gradient (72% Percoll, 64% Percoll, 52% Percoll) and centrifuge at 1545 x g for 30 minutes at room temperature. After carefully discarding the top two cell layers, the third layer containing neutrophils was transferred to a clean 15 ml tube. Cells were washed and counted, then plated at a density of 3 x 10^6 cells/well in 6-well plate. Neutrophil purity was determined by flow cytometry showed in Figure S4.

For inflammasome studies, cells were primed with 100 ng/ml LPS (Sigma Aldrich, L4391) for 3 hours, then with 15 μM nigericin (Sigma Aldrich) for 1 hour, 5mM ATP for 1 hour, or 50 mg/ml bone particles for 2 hours.

**Western blot**

Cell extracts were prepared by lysing cells with RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5% NaDOAc, 0.1% SDS, and 1.0% NP-40) plus complete protease inhibitor cocktail (Roche, CA). For tissue extracts, bone marrow (BM) and BM-free bones were lysed
with RIPA buffer containing protease inhibitors. Protein concentrations were determined by the Bio-Rad Laboratories method, and equal amounts of proteins were subjected to SDS-PAGE gels (12%) as previously described (43). Proteins were transferred onto nitrocellulose membranes and incubated with antibodies against GSDMD (1:1000, ab219800, Abcam), GSDME (1:1000, ab215191, Abcam), β-actin (1:5000, sc-47778, Santa Cruz Biotechnology, TX, USA) overnight at 4°C followed by incubation for 1 hour with secondary goat anti–mouse IRDye 800 (Thermo Fisher Scientific, MA) or goat anti–rabbit Alexa Fluor 680 (Thermo Fisher Scientific, MA), respectively. The results were visualized using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, Nebraska, USA).

**LDH assay**

Cell death was assessed by the release of LDH in conditioned medium using LDH Cytotoxicity Detection Kit (TaKaRa, CA).

**IL-1β and IL-18 ELISA**

IL-1β, IL18 levels in conditioned media were measured by ELISA (eBiosciences, NY).

**ATP assay**

ATP levels in conditioned media were measured by RealTime-Glo Extracellular ATP Assay kit (Promega, WI).

**Flow Cytometry**

Bone marrow cells were flushed from tibias with PBS. Single cell suspensions were labeled with antibodies for 30 minutes at 4°C. Flow cytometry analysis was performed on FACS Canto II. Cell cytometric data was analyzed using FlowJo10.7.1. Full gating strategy was shown in Figures S4 and S5.
RNA isolation and RT-qPCR

RNA was extracted from bone or bone marrow cells using RNeasy Plus Mini Kit (Qiagen). Four millimeters of fracture calluses free of bone marrow were homogenized for mRNA extraction. cDNA were prepared using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems). Gene expression was analyzed by qPCR using SYBR Green (Applied Biosystems) according to the manufacture.

Statistical analysis

Statistical analysis was performed using the Student’s t test, one-way ANOVA with Tukey’s multiple comparisons test as well as two-way ANOVA with Tukey’s multiple comparisons test in GraphPad Prism 8.0 Software.
Results

GSDMD and GSDME were expressed in bone microenvironment

The crucial role that gasdermins (GSDMs) play in inflammation, a response that can be induced by injury, prompted us to analyze their expression in unfractured and fractured mouse tibias. Gsdmd and Gsdme were the only GSDM family members that were readily detected in bone marrow (BM) and BM-free tibias from wild-type (WT) mice (Figure 1A-D and Figure 1-figure supplement 1A-B; Figure 1-figure supplement 2A-B). Expression levels of Gsdmd in BM and BM-free tibias (Figure 1A-C and Figure 1-figure supplement 2A) were consistently higher in fractured compared with unfractured bones. The injury did not affect Gsdme mRNA levels (Figure 1A) but it increased Gsdme protein levels in BM-free tibias (Figure 1-figure supplement 2B). Both GSDMs appeared constitutively cleaved in BM (Figure 1C-D) but not BM-free tibias (figure 1-supplement 2A-B). Since Gsdmd was predominantly expressed in bones, we determined the impact of its loss on the expression of its family members. Gsdmd deficiency increased baseline Gsdme mRNA levels in BM-free tibias but not BM, a response that was unaffected by the injury and did not impact Gsdme protein levels (Figure 1A-D and Figure 1-figure supplement 2A-B). The expression of the other family members was unaltered by Gsdmd deficiency or the injury, with exception of Gsdmc, which was reduced in fractured BM-free tibias (Figure 1-figure supplement 1A-B). Thus, GSDMD and GSDME are present in the bone microenvironment in homeostatic and injury states.

Lack of GSDMD or GSDME delayed fracture healing

When stabilized with an intramedullary inserted pin, fractured murine long bones heal through mechanisms that involve the formation of callus structures (44). To determine the role of GSDMD and GSDME in fracture healing, we assessed callus formation in Gsdmd\(^{-}\), Gsdme\(^{-}\), and Gsdmd\(^{-}\);Gsdme\(^{-}\) mice. The volume of bone callus was higher on day 14 compared with
day 10 post-injury in WT mice (Figure 1e). It increased indistinguishably in Gsdmd<sup>−/−</sup> and Gsdme<sup>−/−</sup> mice on day 14 compared to day 10, but was significantly lower in mutants compared with WT mice (Figure 1E-F). Notably, callus volume was comparable between single and compound mutants (Figure 1E-F), suggesting that both GSDMs share the same signaling pathway in fracture healing. Collectively, these findings indicate that GSDMD and GSDME play an important role in bone repair following fracture injury.

To gain insights onto the mechanisms of fracture healing, we focused on GSDMD as its expression and proteolytic maturation were consistently induced by fracture. Time-course studies revealed that while the callus bone volume increased linearly until day 14 post-fracture and plateaued by day 21 in WT mice (Figure 2A-B), it continued to expand in Gsdmd<sup>−/−</sup> mice until day 21 (Figure 2A-B). The callus volume declined in both mouse strains by day 28 but it was larger in mutants compared with WT controls (Figure 2A). Histological analysis indicated that the areas of the newly formed mesenchyme, cartilage, and bone were smaller in Gsdmd<sup>−/−</sup> compared with WT mice on day 7 (Figure 2C-F). This outcome was also observed on day 10, except for the mesenchyme tissue area, which was larger in Gsdmd<sup>−/−</sup> compared with WT. While cartilage remnants were negligible in WT callus on day 14, they remained abundant in Gsdmd<sup>−/−</sup> counterparts (Figure 2F). Additional histological assessments revealed that the number osteoclasts, which are involved in the remodeling of the newly formed bone, declined after day 14 not only in WT bones as expected, but also in mutants (Figure 2G-I). At any time-point, there were more osteoclasts in injured Gsdmd<sup>−/−</sup> bones compared to WT counterparts. Taken together, these results suggest that the healing process is perturbed in mutant mice.
To determine the impact of GSDMD deficiency on the functional result of bone regeneration, unfractured and 28-day post fracture bones were subjected to biomechanical testing. Injured WT tibias exhibited decreased strength an stiffness compared with unfractured counterparts (Figure 3A-C), indicating that the healing response has not fully recovered bone function at this time-point. Biomechanical properties of unfractured Gsdmd−/− tibias were slightly higher though not statistically significant in Gsdmd−/− compared with WT unfractured bones (Figure 3A-C), findings that were consistent with the higher bone mass phenotype of Gsdmd−/− mice relative to their littermates (29). Notably, fractured bones from Gsdmd−/− mice exhibited lower biomechanical parameters compared with WT controls. Thus, the functional competence of the repaired bone structure is compromised in GSDMD deficient mice.

Expression and secretion of IL-1β and IL-18 were attenuated in the absence of GSDMD

Inflammation characterized by elevated levels of cytokines including those of the IL-1 family underlines the early phase of wound healing (3). Since IL-1β and IL-18 are secreted through GSDMD-assembled plasma membrane pores (21-23), we analyzed the levels of these inflammatory cytokines in the bone marrow supernatants from unfractured and fractured bones (1 day after injury). Baseline secretion levels of IL-1β or IL-18 were comparable between WT and Gsdmd mutants (Figure 4A-B). Fracture increased IL-1β and IL-18 levels in bone marrow supernatants in both groups, but they were significantly attenuated in mutant samples compared with WT controls (Figure 4A-B). Thus, fracture-induced IL-1β and IL-18 levels in bone marrow are attenuated upon loss of GSDMD.

To understand transcriptional regulation of IL-1β and IL-18 in this fracture model, we determined mRNA levels of these cytokines in the BM and BM-free bone compartments. Baseline levels of Il1b and Il18 mRNA were undistinguishable between WT and Gsdmd−/− samples in both compartments (Figure 4C-D). Following fracture, the expression of Il1b and Il18 mRNA was induced in WT but not Gsdmd−/− mice (Figure 4C-D), suggesting a feedback
mechanism whereby these cytokines secreted through GSDMD pores amplified their own expression. Since NLRP3 and absent in melanoma 2 (AIM2) inflammasomes, which sense plasma stimuli such as membrane perturbations and DNA, respectively, are implicated in the maturation of IL-1β, IL-18, and GSDMD (26, 29, 45), we also analyzed the expression of these sensors. Levels of Nlrp3 and Aim2 to some extent (Figure 4C-D) as well as those of Asc and caspase-1 (Figure 4-figure supplement 1A-B) were comparable between WT and Gsdmd−/− samples in homeostatic conditions. Fracture increased the expression of Nlrp3 and Aim2 in WT and mutants only in BM-free bone samples (Figure 4C-D) whereas it induced caspase-1 expression WT cells both compartments. Never was the expression of Nlrc4 and caspase-11 mRNA modulated by the fracture injury nor loss of GSDMD (Figure 4-figure supplement 1A-B).

Thus, the expression of Il1b or Il18 and certain inflammasome components (e.g., Nlrp3, Aim2, Asc, and caspase-1) is transcriptionally regulated in the fracture injury model.

Lack of GSDMD attenuated the secretion of IL-1β and IL-18 induced by danger signals

The high levels IL-1β and IL-18 in bone marrow of fractured bones provided a strong rationale for assessing the presence of neutrophils, monocytes, and macrophages, which harbor high levels of inflammasomes and rapidly accumulate during the first hours after injury (25, 26, 29). Flow cytometry analysis revealed that the abundance of these cells in bone marrow of uninjured bones was unaffected by loss of GSDMD (Figure 5A-C and Figure 5-figure supplement 5). Fracture increased the percentage of neutrophils and monocytes but not macrophages (Figure 5A-C). GSDMD deficiency was associated with a slight decrease and increase in the percentage of neutrophils and monocytes, respectively (Figure 5A-C). Thus, neutrophil and monocyte but not macrophage populations are expanded in fractured bones. GSDMD deficiency appears to slightly attenuate and increase the percentage of neutrophils and monocytes, respectively.
Inflammasome assembly signals include those generated by ATP, which is released by dead cells (46, 47). Therefore, we measured the levels of this danger signal in bone marrow. ATP levels were comparable between WT and Gsdmd<sup>−/−</sup> samples at baseline but were induced by 4-fold after fracture in both groups (Figure 5D). Next, we studied cytokine release by WT and Gsdmd<sup>−/−</sup> cells not only in response to ATP but also bone particles, which are undoubtedly released following bone fracture. Bone particles were as potent as the NLRP3 inflammasome activators, nigericin and ATP, in inducing GSDMD cleavage by LPS-primed macrophages (Figure 5E). Accordingly, these danger signals induced IL-1β release (Figure 5F) and pyroptosis as assessed by the release of lactate dehydrogenase (LDH; Figure 5-figure supplement 3A), responses that were attenuated in GSDMD-deficient macrophages. Both nigericin and ATP robustly stimulated GSDMD cleavage and IL-1β release by LPS-primed neutrophils through mechanisms that partially involved GSDMD, but only nigericin caused neutrophil pyroptosis (Figure 5-figure supplement 3B). Bone particles had no effect on GSDMD maturation and IL-1β and LDH release by neutrophils (Figure 5G-H and Figure 5-figure supplement 6B). Thus, fracture injury creates a microenvironment that induces cytokine secretion through mechanisms involving GSDMD.

**Loss of IL-1 signaling delayed fracture healing**

The inability of Gsdmd<sup>−/−</sup> mice to mount efficient healing responses correlated with low levels of IL-1β and IL-18 in bone marrow, suggesting that inadequate secretion of these cytokines may account for the delayed fracture repair. While the actions of IL-18 in bone are not well defined, overwhelming evidence positions IL-1β as a key regulator of skeletal pathophysiology (48, 49). Therefore, we used IL-1 receptor knockout (Il1r<sup>−/−</sup>) mice to test the hypothesis that IL-1 signaling was required for bone healing following fracture. Bone callus volume was larger on day 14 compared with day 10 in WT and Il1r<sup>−/−</sup> tibias, but it was smaller at both time-points in mutants compared to WT controls (Figure 6A-B). Histological analysis
confirmed that the mesenchyme, cartilage, and bone areas were all smaller in \( \text{Il1r}^{-/-} \) compared with WT mice (Figure 6C-F). Like in \( \text{Gsdmd}^{-/-} \) tissues, cartilage remnants were prominent within the callus of \( \text{Il1r}^{-/-} \) specimens at day 14 (Figure 6F), and the number and surface of osteoclasts were significantly higher at all times in mutant compared to WT mice at day 7, while cartilage and bone areas remained smaller in mutants at day 10 (Figure 6G-I). Although Gsdmd expression was not analyzed in \( \text{Il1r}^{-/-} \) mice, these mutants exhibited delayed fracture healing like \( \text{Gsdmd}^{-/-} \) mice, suggesting that functional GSDMD-IL-1 axis is important for adequate bone healing after fracture.
Discussion

GSDMs are implicated in a variety of inflammatory diseases but their role in bone regeneration after fracture is largely unknown. We found that fracture healing was comparably delayed in mice lacking GSDMD or GSDME; yet concomitant loss of GSDMD and GSDME did not worsen the phenotype. This outcome was unexpected because these GSDMs are activated via distinct mechanisms as GSDMD is cleaved by caspase-11 (mouse ortholog of human caspase-4 and -5), neutrophil elastase and cathepsin G, or caspase-8 whereas GSDME is processed by caspase-3 and granzyme B (34, 39). The phenotype of double knockout mice suggested complex, and possibly convergent actions of these GSDMs in fracture healing. Indeed, the phenotype of either single mutant strain implied non-redundant functions of both GSDMs whereas the outcomes of compound mutants suggested that they shared downstream effector molecules. The latter view was supported by the ability of either GSDM to mediate pyroptosis and IL-1β and IL-18 release in cell a context-dependent manner (35, 37-40). Furthermore, functional complementation of GSDMD by GSDME has also been reported (35). Thus, although additional studies are needed for further insights onto the mechanism of differential actions of GSDMD and GSDME in bone recovery after injury, our findings reinforce the crucial role that inflammation plays during the bone fracture healing process.

In addition to IL-1β and IL-18, inflammatory mediators such as ATP, alarmins (e.g., IL-1α, S100A8/9, high mobility group box 1, and eicosanoids (e.g., PGE2) are expected to be uncontrollably released during pyroptosis (24, 50). Since these inflammatory and danger signals work in concert to inflict maximal tissue damage, we anticipated a milder delay in fracture healing in mice lacking IL-1 receptor compared with GSDM deficient mice. Contrary to our expectation, callus volumes and the recovery time were comparable among all mutant mouse strains. These observations suggested that IL-1 signaling downstream of GSDMs played a non-redundant role in fracture healing. This view was consistent with the reported essential role of IL-1α and IL-1β in bone repair and aligned with the high expression of these
cytokines by immune cells, which are known to massively infiltrate the fracture site (3). Thus, although IL-1 signaling has been extensively studied in various injury contexts, the novelty of this work is its demonstration of the role of GSDM-IL-1 axis in fracture repair.

IL-1 signaling induces the expression of cytokines, chemokines, and growth factors that govern bone remodeling, a process that is initiated by the osteoclasts (51). Consistent with the critical actions of GSDM-IL-1 cascades in bone repair and the osteoclastogenic actions of IL-1β, loss of GSDMD in mice resulted in increased bone mass at baseline as the result of decreased osteoclast differentiation (29). Here, we found that lack of GSDMD was associated with increased number of osteoclasts and their precursors, the monocytes. We surmised that this result was simply a reflection of delayed osteoclastogenesis in mutant mice as the consequence of delayed responses such as neovascularization and development of bone marrow cavity. This view is based by the fact that bone marrow is the site of hematopoiesis in adult animals and vascularization is important for the traffic of osteoclast progenitors. As a result, disruption in either hematopoiesis or vascularization should undoubtedly impact osteoclastogenesis (52). Although our mechanistic studies revolved around myeloid cells from which the osteoclasts arise, it is worth noting that the inflammasome – GSDM pathways are functional in the osteoblast lineage (47, 53, 54). Therefore, osteoblast lineage autonomous actions of these pathways in bone healing cannot be ruled out.

Fracture injury increased the levels of Nlrp3 and its activator ATP in bone marrow, suggesting that the inflammasome assembled by this sensor may be responsible for the activation of GSDMs, particularly, GSDMD. However, more studies are needed to firm up this conclusion since Aim2 was also expressed in bone marrow. Other limitations of this study included i) the lack of data comparing biomechanical properties of fractured bones from all the mutant mouse strains used, ii) the unknown function of IL-18 pathway in fracture healing; iii) the contribution of systemic factors such as glucocorticoids, which are regulated by inflammasome - IL-1β pathways and affect bone healing and strength (55-57); iv) the knowledge gap on
differential expression of GSDMD and GSDME by the various cell types that are activated in response to fracture; and v) the lack of translational studies using drugs such as disulfiram, which inhibits the processing or functions of GSDMD and GSDME (35), to validate genetic mouse findings. Despite these shortcomings, this study has revealed the crucial role that GSDMD and GSDME play in fracture healing (Fig. 7). It also suggests that drugs that inhibit the functions of these GSDMs may have adverse effects on this healing process.
**Figure legends**

**Figure 1.** GSDMD and GSDME were expressed in bone microenvironment and involved in bone callus formation. BM (A, C-D) and BM-free tibias (B) from 12-week-old male WT and *Gsdmd*−/− mice (n=4-5 mice). Samples were isolated from unfractured or fractured tibias (3 days after injury). qPCR (A-B) and Western blot (C-D) analyses. qPCR data were normalized to unfractured WT. E) Bone callus volume was quantified using Scanco software (n=5). F) Representative 3 D reconstructions of bones using µCT. Data were mean ± SD and are representative of at least three independent experiments. Data from male and female mice were pooled because there was no sex difference. **P < 0.01; ***P < 0.001; ****P < 0.0001, two-way ANOVA with Tukey's multiple comparisons test. Scale bar, 1 mm. BM, bone marrow; µCT, micro-computed tomography; WT, wild-type.

**Figure 2.** Loss of GSDMD delayed fracture healing. Tibias of 12-week-old male and female WT or *Gsdmd*−/− mice were subjected to fracture and analyzed at the indicated times. A) Bone callus volume was quantified using Scanco software (n=6). B) Representative 3 D reconstructions of bones using µCT. C-E) Quantification of tissue area by imageJ software (n=5). F) Representative ABH staining. Quantification of Oc.S/BS (G) and N.Oc/BS (H) using Bioquant software (n=5). I) Representative images of TRAP staining. Data were mean ± SD. Data from male and female mice were pooled because there was no sex difference. *P < 0.05; ***P < 0.001; ****P < 0.0001, two-way ANOVA with Tukey's multiple comparisons test. Scale bar, 1 mm (B), 500 µm (F) or 200 µm (I). µCT, micro-computed tomography; WT, wild-type.

**Figure 3.** Loss of GSDMD compromised bone biomechanical properties after fracture. Unfractured or fractured tibias (28 days after injury) from 12-week-old male WT or *Gsdmd*−/− mice were subjected to a torsion test (n=6). A) Bone strength. B) Bone stiffness. c) Bone
toughness. Data were mean ± SD. *P < 0.05; **P < 0.01; ****P < 0.0001, One-way ANOVA with Tukey's multiple comparisons test. ns, non significant WT, wild-type.

**Figure 4.** Loss of GSDMD attenuated the expression and secretion of IL-1β and IL-18 induced by fracture. BM supernatants (A-B) and BM-free bones (c) were from 12-week-old male WT or Gsdmd−/− mice (n=4-5). Samples were isolated from unfractured or fractured tibias (1 day after injury). ELISA (A-B) and qPCR (C-D) analyses. qPCR data were normalized to unfractured WT. Data were mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, two-way ANOVA with Tukey's multiple comparisons test. BM, bone marrow; WT, wild-type.

**Figure 5.** Loss of GSDMD attenuated the secretion of IL-1β and IL-18 induced by danger signals. Cells were isolated from the tibias from 12-week-old female WT or Gsdmd−/− mice. A-C) Cell counts (n=4-5). BM was harvested from unfractured or fractured tibias (2 days after fracture). D) ATP levels. BM supernatants were harvested from unfractured or fractured tibias (24 hours after fracture). Immunoblotting analysis of GSDMD cleavage (e-g) or IL-1β ELISA run in triplicates (F-H). BMDMs were expanded in vitro whereas neutrophils were immediately after purification. Cells were primed with 100 ng/ml LPS for 3 hours, then with 15 μM nigericin for 1 hour, 5 mM ATP for 1 hour, or 50 mg/ml bone particles for 2 hours. Data are mean ± SD and were representative of at least three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, two-way ANOVA with Tukey's multiple comparisons test. BPs, bone particles; cGSDMD, cleaved GSDMD; WT, wild-type.

**Figure 6.** Loss of IL-1 receptor delayed fracture healing. Tibias of 12-week-old male WT or Il1r−/− mice were subjected to fracture and analyzed at the indicated times. A) Bone callus volume was quantified using Scanco software (n=5). B) Representative 3 D reconstructions of bones using μCT. C-E) Quantification of tissue area by imageJ software (n=5). F) Representative
ABH staining. Quantification of Oc.S/BS (G) and Oc.S/BS (H) using Bioquant software (n=5). I)
Representative images of TRAP staining. Data were mean ± SD. *P < 0.05; ***P < 0.001; ****P < 0.0001, two-way ANOVA with Tukey’s multiple comparisons test (A, C-E) or unpaired t-test (G-H). Scale bar, 1 mm (b), 500 µm (f) or 200 µm (i). Il1r, IL-1 receptor; WT, wild-type.

Figure 7. A model of GSDM – IL-1 signaling in fracture healing. Bone fracture is followed by the repair and remodeling phases, which ultimately lead to the restoration of the original bone structure. Fracture causes the release of DAMPs, which activate the inflammasomes and other pathways, leading to the maturation of GSDMD and GSDME, and processing and secretion of IL-1β – IL-18. This model is based on the findings in bold texts indicating that mice lacking GSDMD, GSDME, or defective in IL-1 signaling (owing to the deletion of IL-1 receptor) exhibit delayed fracture healing. Levels of ATP (DAMP), AIM2, NLRP3, and IL-18 are elevated following fracture, but whether these factors are involved in fracture healing was not assessed in this study.

Figure 1-figure supplement 1. Several GSDM family members were barely expressed in bones. RNAs were isolated from BM-free bones (A) or BM (B) were from 12-week-old male WT or Gsdmd−/− mice (n=4-5). Samples were isolated from unfractured or fractured tibias (3 days after injury). qPCR (A-B) analysis. Data were normalized to unfractured WT, and were mean ± SD. *P < 0.05; ***P < 0.001; ****P < 0.0001, two-way ANOVA with Tukey’s multiple comparisons test.

Figure 1-figure supplement 2. Fracture induced GSDMD and GSDME expression. Proteins were isolated from BM-free tibias from 12-week-old male WT or Gsdmd−/− mice. Tibias were unfractured or fractured (3 days after injury). GSDMD (A) and GSDME (B) were analyzed by immunoblotting. cGSDMD, cleaved GSDMD; cGSDME, cleaved GSDME; WT, wild-type.
Fracture induced the expression of certain inflammasome components. RNAs were isolated from BM-free bones (A) or BM (B) were from 12-week-old male WT or Gsdmd⁻/⁻ mice (n=4). Tibias were unfractured or fractured (3 days after injury). RNAs were analyzed by qPCR. Data were normalized to unfractured WT, and were mean ± SD. *P < 0.05; ****P < 0.0001, two-way ANOVA with Tukey’s multiple comparisons test. WT, wild-type.


Gating strategy.  BMDMs (A) were expanded in vitro whereas neutrophils (B) were used immediately after purification. Cells were primed with 100 ng/ml LPS for 3 hours, then with 15 μM nigericin for 1 hour, 5 mM ATP for 1 hour, or 50 mg/ml bone particles for 2 hours. LDH was measured in conditioned medium. Data are mean ± SD of triplicates and were representative of at least three independent experiments. *P < 0.05; ****P < 0.0001, two-way ANOVA with Tukey’s multiple comparisons test. BPs, bone particles; LDH, lactate dehydrogenase; WT, wild-type.

qPCR analysis of Gsdmd and Gsdme expression in BM and BM-free tibias of WT and Gsdmd⁻/⁻ mice.

Bone callus volume of WT, Gsdmd⁻/⁻, Gsdme⁻/⁻, and Gsdmd⁻/⁻;Gsdme⁻/⁻ mice.
Figure 2 - Source data 1. µCT and histological, and histomrphometric analyses of WT and Gsdmd
t− mice.

Figure 3 - Source data 1. Biomechanical analysis of WT and Gsdmd− mice.

Figure 4 - Source data 1. ELISA analysis of IL-1β and IL-18 levels in BM supernatants of WT and
Gsdmd− mice.

Figure 4 - Source data 2. qPCR analysis of gene expression in BM and BM-free tibias of WT and
Gsdmd− mice.

Figure 5 - Source data 1. ELISA analysis of IL-1β and IL-18 levels in WT and Gsdmd− cell culture
supernatants.

Figure 5 - Source data 1. µCT and histological, and histomrphometric analyses of WT and Il-1r−
tmice.

Figure 1-figure supplement 1-source data 1. qPCR analysis of Gsdm expression in BM and
BM-free tibias of WT and Gsdmd− mice.

Figure 1-figure supplement 2-source data 1. qPCR analysis of gene expression in BM and BM-
free tibias of WT and Gsdmd− mice.

Figure 4-figure supplement 1-source data 1. Percentage of LDH release in WT and Gsdmd−
cell culture supernatants.

Acknowledgements

This work was supported by NIH/NIAMS AR076758 and AI161022 grants to GM. JS was
supported by NIH grants AR075860, AR077616, and AR077226; YA-A by NIH grants
AR049192, AR074992, AR072623, and by grant #85160 from the Shriners Hospital for
Children; MJS., by NIH grants AR074992.

Conflict of interests
Dr. Gabriel Mbalaviele is consultant for Aclaris Therapeutics, Inc. All other authors declare no conflict of interest.


51. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone...


Fracture → DAMPs
   ↓
AIM2 inflammasome
   ↓
NLRP3 inflammasome
   ↓
GSDMD – GSDME
   ↓
IL-1β – IL-18
   ↓
Remodeling
Repair →
unstaining

Neutrophil: CD11b+ Ly6G+


Monocyte: Ly6G-, CD11b+, Ly6C+